DUSP6 and ovarian cancer: This suggests that overexpression of DUSP6 may promote chemotherapy-resistance through the negative regulation of the ERK signaling pathway, which increases the G0/G1 phase ratio among ovarian cancer cells leading to their cellular quiescence.